UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of USD 25 / HKD 39, indicating a potential upside of +60% from the current price of HKD 24.0 [2][12] Core Insights - The company has established an integrated platform for new drug development and commercialization over its 20+ years in the pharmaceutical industry. The anticipated approval of new innovative drugs, such as Syk inhibitor Solipnib, is expected to elevate the company's growth trajectory [2][3] - The company is preparing for the commercialization of Solipnib, which is expected to be approved in 2024 for the treatment of second-line immune thrombocytopenic purpura (ITP), with a projected peak sales contribution of approximately RMB 600 million [2][3] - The report highlights the uncertainty surrounding the approval of the drug Fuhuitin for second-line gastric cancer in China, despite positive data from clinical trials [2][3] Financial Projections - Revenue projections for the company from 2023 to 2025 are estimated at USD 849 million, USD 788 million, and USD 976 million, respectively, reflecting a compound annual growth rate (CAGR) of 32% [3][20] - The report forecasts a return to profitability in 2023 with a net profit of USD 31 million, followed by losses of USD 131 million in 2024 and USD 19 million in 2025 [3][20] - The company's financial metrics indicate a significant increase in revenue from USD 356 million in 2021 to an estimated USD 849 million in 2023, representing a year-on-year growth of 99% [3][20] Market Expectations - The report outlines optimistic and pessimistic scenarios for the company's revenue growth, with an optimistic target price of HKD 47.1 and a pessimistic target price of HKD 19.6, reflecting varying expectations for revenue CAGR [19][20] - The market's expected price range for the company's stock is between HKD 21.6 and HKD 61.6, with the current price at HKD 24.0 [5][12]

Shares of HUTCHMED (HCM) have gained 2.2% over the past four weeks to close the last trading session at $14.59, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.54 indicates a potential upside of 75.1%.The average comprises five short-term price targets ranging from a low of $14.60 to a high of $45, with a standard deviation of $12.20. While the lowest estimate indicates an i ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that data from FRUTIGA, HUTCHMED's Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology ("ASCO") Plenary Series Session on February 6, 2024. The full presentation can be found here. Fruquintinib is a selec ...

Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor Inmagene retains rights to develop and commercialize both assets worldwide SAN DIEGO, Feb. 2, 2024 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company"), a clinical stage biotechnology company developing innovative and differentiated therapies for imm ...

智通财经APP讯，和黄医药(00013)发布公告，创响生物(Inmagene Biopharmaceuticals)根据2021年1月11日所宣布的战略合作条款，已行使与和黄医药发现的两款候选药物IMG-007和IMG-004授权许可相关的选择权(以下简称“选择权”)。行使选择权并于和黄医药收到创响生物约7.5%的普通股股份(完全稀释)后，创响生物将取得在全球进一步开发、生产和商业化上述两款候选药物的独家权益。 作为合作协议的一部分，和黄医药向创响生物授予多种候选药物仅限于用于治疗免疫性疾病的独家选择权。自选择权协议实施以来，创响生物注入资金并领导将其中两款候选药物IMG-004和IMG-007推向临床开发。对于IMG004和IMG-007中的每款候选药物，和黄医药有权收取最高可达9250万美元的开发里程碑付款和最高可达1.35亿美元的潜在的商业销售里程碑付款，以及商业化后分成。 2023年，创响生物启动了两项IMG-007(一种研究性的OX40拮抗性单克隆抗体)用于治疗中度至重度特应性皮炎和斑秃的全球IIa期临床试验。它还完成了IMG-004的I期单次剂量递增(SAD)研究，IMG-004是一种可逆、非共 ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announced that, Inmagene Biopharmaceuticals ("Inmagene") has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the "Options") pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares represen ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The Engli ...

Core Viewpoint - HUTCHMED (China) Limited is set to announce its final results for the year ended December 31, 2023, on February 28, 2024, indicating a significant upcoming event for investors and analysts [1]. Group 1: Financial Results Announcement - The final results announcement will occur at 6:30 am EST / 11:30 am GMT / 7:30 pm HKT on February 28, 2024 [1]. - A conference call and audio webcast presentation with Q&A will follow the results announcement, scheduled for 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on the same day [2]. Group 2: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [3]. - The company employs approximately 5,000 personnel, with a core team of about 1,800 dedicated to oncology and immunology [3]. - HUTCHMED has successfully brought three cancer drug candidates to market in China, with the first also marketed in the U.S. [3].

— First medicine approved under new "1+" mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade — — Fruquintinib already approved in mainland China, Macau SAR and the United States — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limit ...